INO-4201

BIOLOGICAL2 trials

Sponsors

Inovio Pharmaceuticals, University of Geneva, Switzerland

Conditions

Ebola VaccineEbola Virus Disease

Phase 1

Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers

CompletedNCT02464670

Inovio PharmaceuticalsEbola Vaccine

Start: 2015-05-31End: 2018-05-24Updated: 2019-06-28

INO-4201 as Booster in Healthy VSV-ZEBOV Vaccinees

CompletedNCT04906629

University of Geneva, SwitzerlandEbola Virus Disease

Start: 2021-09-01End: 2022-05-11Updated: 2022-05-24

Related Papers

Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers

The Journal of Infectious Diseases2019-03-19119 citations